芪术肺纤汤治疗特发性肺间质纤维化的临床疗效观察  

Clinical Observation on the Therapeutic Effect of Qizhu Feixian Decoction on Idiopathic Pulmonary Interstitial Fibrosis

作　　者：张雯静 尹建坤 李萌[1] 李辉[1] 李光熙[1] 王秋铭 高扬[1] 刘世刚[1] 李国勤[1] ZHANG Wenjing;YIN Jiankun;LI Meng;LI Hui;LI Guangxi;WANG Qiuming;GAO Yang;LIU Shigang;LI Guoqin(Guang'anmen Hospital,China Academy of Chinese Medical Sciences,Beijing 100053,China)

机构地区：[1]中国中医科学院广安门医院,北京100053

出　　处：《中国中医基础医学杂志》2024年第3期479-483,共5页JOURNAL OF BASIC CHINESE MEDICINE

基　　金：国家自然科学基金青年项目(82004347);中央本级重大增减支项目-名贵中药资源可持续利用能力建设项目(2060302)。

摘　　要：目的探索芪术肺纤汤治疗特发性肺间质纤维化(idiopathic pulmonary fibrosis,IPF)患者的临床疗效。方法纳入40例2019年10月1日至2021年12月31日于中国中医科学院广安门医院就诊及住院的IPF患者,随机分为试验组和对照组各20例,对照组患者口服乙酰半胱氨酸胶囊加百令胶囊,试验组患者在此基础上加用芪术肺纤汤,治疗3个月后观察2组患者肺功能、6分钟步行距离(six-minute walk distance,6MWD)、静息状态血氧饱和度(oxygen saturation,SpO_(2))、圣乔治呼吸问卷(the Saint George's respiratory questionnaire,SGRQ)评分、血清涎液化糖链抗原6(krebs von den lungen-6,KL-6)水平、高分辨CT(high-resolution ct,HRCT)半定量评分变化。结果治疗后试验组患者一氧化碳弥散量占预计值的百分比(carbon monoxide diffusing capacity/predict value,DLCO%)明显高于对照组,差异有统计学意义(P<0.01);治疗后试验组SGRQ总分、症状评分、疾病影响评分、血清KL-6和HRCT半定量评分均低于对照组,差异有统计学意义(P<0.05);肺功能分级和HRCT半定量评分呈正相关性(r=0.849,P<0.01)。结论芪术肺纤汤能够延缓IPF患者的肺纤维化进展,值得临床推广应用。Objective To explore the clinical effect of Qizhu Feixian decoction on idiopathic pulmonary fibrosis(IPF)patients.Methods A total of 40 IPF patients admitted to Guang'anmen Hospital,China Academy of Chinese Medical Sciences from October 1st,2019 to December 31st,2021 were included,and divided into trial group and control group at random,with 20 cases in each group.The control group was given acetylcysteine capsules plus Bailing capsules,and the trial group was given Qizhu Feixian decoction in addition.After 3 months of treatment,the pulmonary function,6-minute walk distance(6MWD),resting oxygen saturation(SpO_(2)),the sores of the Saint George's respiratory questionnaire(SGRQ),serum krebs von den lungen(KL)-6 level,and the semi-quantitative scores of high-resolution ct(HRCT)were observed in both groups.Results After treatment,the carbon monoxide diffusing capacity/predict value(DLCO%)in the trial group was obviously higher than that in the control group(P<0.01).After treatment,the total scores of SGRQ,the scores of symptom,the scores of influence of disease,the level of KL-6,and the scores of HRCT in the trial group were lower than those in the control group(P<0.05).There was a positive correlation between lung function grade and HRCT semi-quantitative scores(r=0.849,P<0.01).Conclusion Qizhu Feixian decoction can delay the progression of pulmonary fibrosis in patients with IPF.It is worthy of further promotion.

关 键 词：芪术肺纤汤 特发性肺间质纤维化 肺功能 SGRQ KL-6 HRCT 

分 类 号：R259[医药卫生—中西医结合]